20 articles
Natural flavonoid fisetin activates mitophagy and xenophagy pathways to restrict intracellular Salmonella growth in immune cells.
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
Small NIH study tests oral drug tofacitinib as potential new treatment for systemic lupus erythematosus with fewer side effects.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions โ from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
FIRST-RA study follows 300 patients to measure early pain relief and functional improvements with filgotinib treatment.
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
Small study explores how tofacitinib may address chronic pain that persists even when inflammation is controlled in RA patients.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
Clinical trial results for oral icotrokinra in treating plaque psoriasis across adult and adolescent patients published in NEJM.
Icotrokinra, a breakthrough oral peptide targeting IL-23, demonstrates significant skin clearance in psoriasis with sustained benefits through 52 weeks.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
A completed Phase 3 trial evaluated whether the anti-TNF biologic infliximab safely and effectively treats plaque psoriasis.
Scientists used CRISPR to find SPART, a human gene that restricts a whole family of dangerous flaviviruses including Zika and dengue.
Scientists develop potent ฮฑ5ฮฒ1 integrin inhibitor for inhalation therapy, offering new approach for severe asthma patients.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
New research identifies key factors behind difficult-to-treat RA and highlights JAK inhibitors as promising therapy option.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
A new review reveals how cellular crosstalk, non-coding RNAs, and lung microbiota drive pulmonary fibrosis โ and where treatments may break through.
JAK inhibitors outperform traditional treatments for rheumatoid arthritis but carry cardiovascular and infection risks.
